Key clinical point: Calcitonin gene-related peptide-antagonists, such as rimegepant and Ubrogepant, can be used for treating acute migraine due to their favorable efficacy and safety, whereas lasmiditan, despite showing promising efficacy, may increase the risk for adverse events (AE).
Major finding: Compared with other drugs, 100 mg ubrogepant showed the highest surface under the cumulative ranking curve (SUCRA) for providing quick pain freedom at 2 hours (0.79) and sustained pain freedom for over 24 hours (0.74), and 75 mg rimegepant showed the highest SUCRA for providing freedom from photophobia within 2 hours (0.96). Although both 100 mg and 200 mg lasmiditan provided relief from headache pain at 2 hours, they increased the risk for AE.
Study details : Findings are from a network meta-analysis of 18 studies including 22,429 patients with migraine who received lasmiditan, rimegepant, ubrogepant, and zavegepant.
Disclosures: This study was supported by the Fundamental Research Funds for the Central Universities, China. The authors declared no conflicts of interest.
Source: Deng X, Zhou L, Liang C et al. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: Systematic review and network meta-analysis of randomised trials. J Headache Pain. 2024;25:16. doi: 10.1186/s10194-024-01723-4 Source